Search
Filters
Clear All
  • 10

Phase

  • 1
  • 1
  • 8
  • 10
  • 9

Found 10 jean-molleston-md trials

A listing of jean-molleston-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Biliary Atresia Study in Infants and Children (BASIC)

J
Jean Molleston, MD
1 - 100
All genders
The purpose of this study is to collect medical information on children with Biliary Atresia so that researchers will be able to learn more about the natural history of Biliary Atresia and its causes.
Learn More

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia (BOLD-EXT)

J
Jean Molleston, MD
All genders
Phase 3
Interventional
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250)Children with Biliary Atresia
Learn More

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)

J
Jean Molleston, MD
1 - 18
All genders
Phase 2
Interventional
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm,domized, controlled trial of immunosuppressive therapy for children with acute liverure. The study will determine if suppressing inflammatory responses with eitherds or equine anti-thymocyte globulin therapy improves survival for children withhis rare, life-threatening condition.
Learn More

Longitudinal Study of Mitochondrial Hepatopathies (MITOHEP)

J
Jean Molleston, MD
18 or below
All genders
Observational
The specific aims of this study are (1) to determine the clinical phenotypes and natural history of hepatic RC and FAO disorders, (2) to determine the correlation between genotyped phenotype, (3) to determine if circulating biomarkers reflect diagnosis and predict liver disease progression and survival with the native liver, (4) …
Learn More

Liver Stiffness in Patients with Underlying Polycystic Kidney Disorders.

J
Jean Molleston, MD
3 - 65
All genders
Use Fibroscan to determine thevalence of CHF in an ADPKD population and the incidence over a four-yeard in these patients. Use Fibroscan to determine thevalence of congenital hepatic fibrosis in an ARPKD population Use fibroscan to determine thevalence of fibrotic liver disease in patients with other cystic kidneydiseases such as …
Learn More

Longitudinal Study of Mitochondrial Hepatopathies (MITOHEP)

J
Jean Molleston, MD
18 or below
All genders
The purpose of this study is to help researchers learn more about these rare liver diseases that occur in infants, children, and young adults.
Learn More

Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) (LOGIC)

J
Jean Molleston, MD
25 or below
All genders
Observational
Cholestasis is a condition in which bile is not properly transported from the liver to the. Cholestasis can be caused by an array of childhood diseases, including the genetic diseases Alagille syndrome (ALGS), alpha-1 antitrypsin (a-1AT) deficiency, bile acidynthesis and metabolism defects, and progressive familial intrahepatic cholestasis (PFIC) or benign …
Learn More

Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Database 2

J
Jean Molleston, MD
2 - 17
All genders
The purpose of the NAFLD Pediatric Database 2 is to better understand nonalcoholic fatty liver disease (''NAFLD) by following and evaluating children with this condition yearly.
Learn More

A Randomized Double-Blind Evaluation of the Pharmacokinetics Safety and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection

J
Jean Molleston, MD
100 or below
All genders
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of TAF against the Hepatitis B Virus in all of the enrolled adolescent subjects.
Learn More

Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)

J
Jean Molleston, MD
25 or below
All genders
The purpose of this study is to collect over a period of 10 years a database, (collection of medical information), which will provide an improved understanding of the effects of these liver diseases as well as to the causes, outcome, and complications of
Learn More